Trial Profile
A Phase 1/2 Trial of MLN0264 in Previously Treated Asian Patients With Advanced Gastrointestinal (GI) Carcinoma (Phase 1) or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma (Phase 2) Expressing Guanylyl Cyclase C (GCC)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Indusatumab vedotin (Primary)
- Indications Adenocarcinoma; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Takeda Oncology
- 23 Mar 2015 New trial record